Maze Therapeutics, Inc. Common Stock MAZE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20M— | —— | —— | $0— | —— | ||
| $34.15M+23.9% | $27.57M+9.4% | $25.19M-10.4% | $28.11M+1.9% | $27.58M+24.1% | ||
| $12.41M+18.3% | $10.49M+34.9% | $7.78M-7.1% | $8.37M+7.0% | $7.82M+4.1% | ||
| $46.55M+22.3% | $38.06M+15.5% | $32.97M-9.6% | $36.47M+3.0% | $35.4M+19.1% | ||
| -$26.55M+30.2% | -$38.06M-15.5% | -$32.97M+9.6% | -$36.47M-3.0% | -$35.4M— | ||
| -132.8%— | —— | —— | —— | —— | ||
| $866K— | —— | —— | —— | —— | ||
| $2.35M— | —— | —— | —— | $2.62M— | ||
| -$24.21M+30.0% | -$34.57M-14.9% | -$30.09M+10.7% | -$33.68M-2.7% | -$32.79M— | ||
| -121%— | —— | —— | —— | —— | ||
| -$0.45+25.0% | -$0.60+9.1% | -$0.66+14.3% | -$0.77+33.0% | -$1.15-105% | ||
| -$26.11M+30.5% | -$37.56M-15.9% | -$32.39M+9.6% | -$35.83M-3.2% | -$34.72M— | ||
| -130.5%— | —— | —— | —— | —— | ||
| -$26.55M+30.2% | -$38.06M-15.5% | -$32.97M+9.6% | -$36.47M-3.0% | -$35.4M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Maze Therapeutics, Inc. Common Stock's revenue?
- Maze Therapeutics, Inc. Common Stock (MAZE) generated $187.5M in revenue over the trailing twelve months.
- Is Maze Therapeutics, Inc. Common Stock profitable?
- Maze Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $122.5M over the trailing twelve months, a -65.4% net margin.
- What is Maze Therapeutics, Inc. Common Stock's earnings per share?
- Maze Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.48.
- Where does Maze Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Maze Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
